ZIOPHARM Oncology market cap is $647.1 m, and annual revenue was $146 k in FY 2018

ZIOPHARM Oncology Net income (Q2, 2020)-18.6 M

ZIOPHARM Oncology EBIT (Q2, 2020)-18.6 M

ZIOPHARM Oncology Cash, 30-Jun-2020153.5 M

ZIOPHARM Oncology EV494.8 M

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|

## Revenue | 667.0k | 800.0k | 800.0k | 1.4m | 4.3m | 6.9m | 6.4m | 146.0k |

| 72% | 216% | 58% | |||||

## R&D expense | 57.1m | 83.4m | 42.9m | 32.7m | 106.8m | 157.8m | 45.1m | 34.1m |

## General and administrative expense | 15.0m | 19.5m | 15.7m | 12.2m | 17.6m | 14.4m | 14.8m | 19.9m |

## Operating expense total | 72.1m | 103.0m | 58.5m | 44.9m | 124.4m | 172.2m | 59.9m | 54.1m |

## EBIT | (71.4m) | (102.2m) | (57.7m) | (43.5m) | (120.1m) | (165.3m) | (53.5m) | (53.9m) |

| (10705%) | (12771%) | (7214%) | (3168%) | (2772%) | (2409%) | (837%) | (36922%) |

## Net Income | (63.8m) | (96.1m) | (57.1m) | (31.8m) | (120.1m) | (165.3m) | (54.3m) | (53.1m) |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|

## Cash | 104.7m | 73.3m | 68.2m | 42.8m | 140.7m | 81.1m | 70.9m | 61.7m |

## Accounts Receivable | 79.0k | 58.0k | 145.0k | 145.0k | 446.0k | 508.4m | 19.0k | 1.9m |

## Prepaid Expenses | 1.3m | 6.9m | 1.9m | 1.1m | 11.4m | 19.8m | 20.7m | |

## Inventories | 23.8m | |||||||

## Current Assets | 106.1m | 80.3m | 70.3m | 44.1m | 152.5m | 104.9m | 90.8m | 84.3m |

## PP&E | 1.1m | 2.0m | 801.0k | 531.0k | 581.0k | 843.0k | 1.2m | 1.1m |

## Total Assets | 108.1m | 83.4m | 71.8m | 45.2m | 153.7m | 106.3m | 105.6m | 95.1m |

## Accounts Payable | 1.7m | 1.5m | 422.0k | 2.0m | 2.0m | 156.0k | 4.4m | 707.0k |

## Short-term debt | ||||||||

## Current Liabilities | 13.4m | 18.9m | 7.8m | 10.8m | 18.1m | 15.8m | 20.9m | 9.5m |

## Long-term debt | ||||||||

## Total Debt | ||||||||

## Total Liabilities | 36.5m | 35.0m | 22.4m | 11.4m | 66.4m | 58.3m | 58.4m | 9.5m |

## Common Stock | 69.0k | 83.0k | 100.0k | 104.0k | 132.0k | 143.0k | 161.0k | |

## Preferred Stock | ||||||||

## Additional Paid-in Capital | 246.5m | 325.2m | 386.5m | 406.3m | 579.9m | 615.5m | 651.7m | |

## Retained Earnings | (283.7m) | (372.6m) | (492.7m) | (658.0m) | (712.4m) | (566.3m) | ||

## Total Equity | 71.6m | 48.4m | 49.4m | 33.8m | 87.4m | (77.3m) | (96.8m) | 85.6m |

## Financial Leverage | 1.5 x | 1.7 x | 1.5 x | 1.3 x | 1.8 x | -1.4 x | -1.1 x | 1.1 x |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|

## Net Income | (63.8m) | (96.1m) | (57.1m) | (31.8m) | (120.1m) | (165.3m) | (54.3m) | (53.1m) |

## Depreciation and Amortization | 268.0k | 658.0k | 738.0k | 462.0k | 357.0k | 290.0k | 369.0k | 575.0k |

## Accounts Receivable | (79.0k) | 21.0k | (87.0k) | (301.0k) | 425.0k | 2.0k | (1.8m) | |

## Accounts Payable | 696.0k | (218.0k) | (1.1m) | 1.6m | 4.0k | (1.9m) | 4.3m | (3.7m) |

## Cash From Operating Activities | (38.8m) | (78.8m) | (59.5m) | (36.6m) | (10.0k) | (58.3m) | (54.7m) | (49.5m) |

## Purchases of PP&E | (1.2m) | (1.6m) | (132.0k) | (193.0k) | (412.0k) | (551.0k) | (737.0k) | (459.0k) |

## Cash From Investing Activities | (1.2m) | (1.6m) | (131.0k) | (193.0k) | (412.0k) | (551.0k) | (737.0k) | (459.0k) |

## Cash From Financing Activities | 84.3m | 49.0m | 54.5m | 11.4m | 98.3m | (788.0k) | 45.3m | 40.3m |

## Net Change in Cash | 44.3m | (31.4m) | (5.1m) | (25.4m) | 97.9m | (59.7m) | (10.1m) | (9.6m) |

## Interest Paid | ||||||||

## Income Taxes Paid |

USD | Q3, 2010 |
---|---|

## Financial Leverage | 1.6 x |